Innovators in Cancer Immunology: Lymphoma
Cancer researchers are uncovering new insights using our Phenoptics™ Quantitative Pathology Research Solutions. In a lymphoma cancer case study, Dr. Rodig uses t...
Michael Feldman, MD, PhD
Associate Professor of Pathology and Laboratory Medicine
Hospital of the University of Pennsylvania Philadelphia, PA
To advance the understanding of disease mechanisms in cancer, it is critical that researchers see everything a tumor has to show them. Leveraging PerkinElmer’s Phenoptics™ Quantitative Pathology Research Solutions, researchers are now visualizing and measuring tumor cells and multiple immune-cell phenotypes simultaneously for the first time in formalin-fixed paraffin-embedded (FFPE) tissue.
Because of Phenoptics’ integration of multiplexed immunohistochemistry and imaging, leading scientists are now able to quantitatively capture systems biology data in cellular detail. What follows are brief profiles of some of these Innovators in Cancer Immunology and how they are using Phenoptics to discover new insights into the complexity of immune-cancer interactions that affect countless millions of patients around the world.
Dr. Michael Feldman is a longtime thought leader in the drive to modernize pathology. He has been actively integrating image analysis, algorithms, digital imaging technology, and informatics to address the shortcoming of conventional immunohistochemistry (IHC) and visual perception. Dr. Feldman is an early adopter of PerkinElmer’s Phenoptics™ technology, and today is focusing on merging quantitative pathology approaches with digital pathology platforms, workflows, and laboratory information systems., Dr. Feldman most recently used Phenoptics imaging capabilities to automate the challenging visual task of assessing TIL counts on conventional, 3-color,chromogenic immunohistochemistry (IHC) instrument.
